Back to Ovarian Cancer
This trial is complete. It is no longer accepting participants. Results may be available on ClinicalTrials.gov.

NCT04539327

NCT04539327
Completed Not Applicable

Who may be able to join

Who might be able to join this trial:

  • You must be willing to sign a consent form if you are able to be contacted and are alive (in some cases, consent may not be needed for patients who cannot be reached, depending on legal and ethical rules in Spain)
  • You must have been diagnosed with a specific type of cancer — high-grade ovarian cancer, fallopian tube cancer, or primary peritoneal cancer — confirmed by a tissue sample (biopsy), and must have been treated through a special medication access program in Spain called the Rucaparib Access Program (RAP)
  • You must be a woman who was 18 years old or older at the time of your diagnosis

Who may not be able to join:

  • You would not be eligible if your medical records are unavailable, missing, incomplete, or cannot be retrieved

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

Trial details

Status
Completed
Phase
Not Applicable
Sponsor
Grupo Español de Investigación en Cáncer de Ovario
Registry
clinicaltrials_gov
Start date
29 July 2020
Est. completion
31 July 2021

Where this trial is recruiting

🇪🇸 Spain

Primary endpoints

Number of Participants With Relevant Co-morbidities; Other Previous Cancers?; Family History of Cancers?; FIGO STAGE; Tumor Histology; BCRA Status; Deficiencies in Other Genes Involved in Homologous Recombination; Surgeries Before Rucaparib; Previous Lines; PARPi Before Rucaparib; Average Dose of Rucaparib Received Per 12 Hours; Rucaparib Drug Exposure; Dose Reductions; Number of Dose Interruptions; Duration of Response (DoR); End of Treatment; Objective Response Rate (ORR); Progression-free Survival (PFS); Radiological Best Overall Response; Biological Best Overall Response

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

View original record on ClinicalTrials.gov